Evonik's 40% Earnings Surge Draws Two Hold Ratings and Only One Higher Target

Evonik's sharp rebound in underlying profit has done little to unify the analyst community, with two of Germany's most closely watched research houses reaching the same "Hold" verdict for entirely different reasons. Deutsche Bank Research kept its price target at EUR 18 on Wednesday, while Berenberg lifted its own from EUR 20.00 to EUR 22.50 — a divergence that leaves investors weighing operating momentum against a market bar that was set higher still.

The specialty chemicals maker reported on Tuesday that adjusted EBITDA for the third quarter of 2026 climbed 40% to EUR 629 million, a comparison drawn against the prior-year period. Revenue advanced 13% to EUR 3.825 billion over the same stretch, meaning the operating result outgrew the top line. Higher prices and larger sales volumes drove the improvement, according to Handelsblatt.

Yet the headline gain masks a more complicated picture at the bottom of the income statement. The quarterly report disclosed a net loss of EUR 53 million, weighed down in part by restructuring provisions of EUR 313 million. Adjusted figures and the result below the line, in other words, tell two different stories.

Consensus, Not Comparison, Sets the Bar

For Deutsche Bank Research, the issue is not whether Evonik improved — it clearly did — but whether the improvement cleared what the market had already baked in. The results landed 1% below consensus, and the midpoint of the company's EBITDA guidance range for 2026 sits slightly under market expectations. That combination explains why the house left its EUR 18 target untouched.

Berenberg takes a different view of the same numbers. Alongside its higher target, the broker highlighted the strong cash generation Evonik delivered and said the figures should not derail BASF's takeover ambitions. Both firms, notably, stopped short of upgrading their recommendation.

The stock itself responded positively, adding 2.2% on Wednesday — a move that sits awkwardly beside the unchanged investment ratings. Shareholders therefore face a split signal: price momentum on one side, cautious analyst stances on the other.

Guidance Points Beyond the Quarter

Evonik's outlook, fleshed out on Tuesday, gives the analyst reactions a longer runway. Management expects adjusted EBITDA of between EUR 2.0 billion and EUR 2.2 billion for 2026, with the result anticipated in the upper half of that band. That is a company forecast rather than a realized full-year figure, and it frames how the quarterly beat should be read.

Strategically, Evonik has drawn its own line in the sand. On Friday the company said it would not enter negotiations with BASF and intends to keep developing as an independent business, though the board remains open to an informative, confidential exchange. Tagesschau reported on Tuesday that Evonik also rejected a raised offer of EUR 24 per share.

Berenberg's assessment suggests the takeover interest still forms part of the valuation case, even after that rejection. What emerges is a stock pulled by two competing yardsticks: the earning power of a standalone Evonik, and the potential significance of BASF's interest. Neither the operational recovery nor the takeover speculation, on the evidence of Wednesday's notes, is enough on its own to turn either house into a buyer.